Compare Heron Therapeutics Inc (HRTX) vs iShares 7-10 Year Treasury Bond ETF (IEF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs iShares 7-10 Year Treasury Bond ETF — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while iShares 7-10 Year Treasury Bond ETF trades at $89.5 (market cap $41.24B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 557× Heron Therapeutics Inc's market cap, and iShares 7-10 Year Treasury Bond ETF is more actively traded (9,141,967 versus 3,668,095). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and iShares 7-10 Year Treasury Bond ETF for 108 Days on average.
| HRTX | IEF | |
|---|---|---|
Market Cap | $74.04M | $41.24B |
Volume | 3,668,095 | 9,141,967 |
Sector | Health | Fixed Income |
52-Week High | $1.49 | $97.99 |
52-Week Low | $0.27 | $88.92 |
Typical Hold Time | 35 Days | 108 Days |
Enterprise Value | $180.78M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
IEF trades at $89.11, showing minimal daily movement with a slight decline of 0.02%. Technical indicators signal a bearish trend with moving averages overwhelmingly negative, though oscillators suggest potential oversold conditions. Recent dividend distributions of $0.31-$0.33 per share provide income support. The bond ETF faces headwinds from rising Treasury yields and inflation concerns, with market sentiment leaning defensive amid ongoing bond market volatility.
The outlook remains cautious as IEF navigates the highest Treasury yields in decades. While current yields create potential entry points for income-focused investors, persistent inflation and Federal Reserve policy uncertainty pose significant risks. The ETF's defensive positioning may appeal during market turbulence, but further yield increases could pressure prices lower.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →
